𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?

✍ Scribed by Adam S. Garden; Joshua A. Asper; William H. Morrison; Naomi R. Schechter; Bonnie S. Glisson; Merrill S. Kies; Jeffrey N. Myers; K. Kian Ang


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
101 KB
Volume
100
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND

Many patients with small primary tumors of the oropharynx have AJCC Stage III/IV disease on the basis of lymphadenopathy. In the current retrospective study, the authors hypothesized that these patients have high rates of locoregional control when treated with radiotherapy, either alone or combined with neck surgery, and may not require concurrent chemotherapy.

METHODS

Two hundred ninety‐nine patients met staging and inclusion criteria. Stage distribution was as follows: T1, 99 patients (33%); T2, 182 patients (61%); Tx, 18 patients (6%); N1, 74 patients (25%); N2, 170 patients (57%); N3, 39 patients (13%); and Nx, 16 patients (5%). Primary tumor resection or tonsillectomy had been performed in 36 patients (12%) and excisional lymph node biopsy or formal neck dissection in 192 patients (64%). Thirty‐three additional patients (10%) received chemotherapy and were analyzed separately.

RESULTS

The median follow‐up was 82 months (range, 8–299 months). The actuarial 5‐year rates of locoregional failure, distant metastases, and overall survival were 15%, 19%, and 64%, respectively. T status was associated with the 5‐year rate of locoregional control: 95% for patients with T1‐/Tx disease, compared with 79% for patients with T2 disease (P < 0.01). The 5‐year rate of distant metastases for patients with N1/2a disease was 11%, compared with 28% for patients with N2b/N2c/N3 disease (P < 0.001).

CONCLUSIONS

Patients with early–T status oropharyngeal carcinoma, which is considered advanced due to the presence of lymphadenopathy, have high rates of locoregional control when treated with radiotherapy without or with neck surgery. Local treatment intensification by the addition of concurrent chemotherapy to radiotherapy would not significantly benefit most of these patients. Cancer 2004. © 2004 American Cancer Society.


📜 SIMILAR VOLUMES


Toxicity of two cisplatin-based radioche
✍ Dirk Rades; Fabian Fehlauer; Mashid Sheikh-Sarraf; Nadja Kazic; Hiba Basic; Robe 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

## Abstract ## Background. This nonrandomized study compared 2 radiochemotherapy regimens for toxicity in 128 patients with stage III/IV head and neck cancer. ## Methods. Patients received conventionally fractionated radiotherapy. The total dose to primary tumor and involved lymph nodes did depe

Prediction of treatment outcome by cispl
✍ Frank J.P. Hoebers; Dick Pluim; Marcel Verheij; Alfons J.M. Balm; Harry Bartelin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 188 KB

## Abstract The purpose of our study was to test the predictive value of cisplatin‐DNA adduct levels in head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin‐radiation. Patients with advanced‐stage HNSCC were treated within a randomized trial, investigating the optimal route

Mature results of a Phase III randomized
✍ David J. Adelstein; Pierre Lavertu; Jerrold P. Saxton; Michelle Secic; Benjamin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

The current study presents mature results from a Phase III randomized trial comparing radiation therapy and concurrent chemoradiotherapy in patients with resectable American Joint Committee on Cancer Stage III and IV disease.